血乳酸作为肌萎缩侧索硬化生存与体重下降的预后生物标志物:探索-验证研究
该回顾性研究纳入澳大利亚探索队列110例ALS患者及86名健康对照,以及日本验证队列36例患者,分析血乳酸与生存和体重下降的关联。探索队列中乳酸低于Q1(1.05 mmol/L)与更短生存相关(p=0.031),校正后每1 SD乳酸升高对应死亡风险降低(HR=0.57,95%CI 0.35-0.91),验证队列确认该关联(p=0.003)。乳酸与3个月BMI变化独立相关(β=0.53,p=0.032),低乳酸患者BMI下降更显著(p=0.010)。
要点
- 较低血乳酸与ALS患者更早死亡风险增加独立相关。
- 低乳酸患者3个月BMI下降更显著,提示乳酸反映营养状态。
- 血乳酸或可作为ALS预后生物标志物,需进一步验证。
核心结论
- 较低血乳酸与ALS患者死亡风险增加和体重下降更显著相关,提示乳酸是营养状态的预后生物标志物。
研究设计与样本
- 回顾性研究,含澳大利亚探索队列110例ALS患者(57例有ΔBMI数据)和86名健康对照,以及日本验证队列36例患者(17例有ΔBMI数据)。
主要发现
- 探索队列中乳酸低于Q1(1.05 mmol/L)与更短生存相关(p=0.031)。
- 探索队列中乳酸每升高1 SD,校正后死亡风险HR=0.57(95%CI 0.35-0.91)。
- 验证队列确认低乳酸与更短生存的关联(p=0.003)。
- 乳酸与3个月BMI变化独立相关(β=0.53,p=0.032),低乳酸患者BMI下降更显著(p=0.010)。
临床怎么用
- 对ALS患者可考虑检测血乳酸以辅助评估生存预后和营养状态风险。
局限性
- 回顾性设计,探索队列和验证队列样本量有限,ΔBMI数据缺失较多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lactate is increasingly recognized as an energy substrate, but its relevance to amyotrophic lateral sclerosis (ALS) remains unclear. We examined whether blood lactate is associated with survival and weight loss in ALS. METHODS: This retrospective study included an Australian exploratory cohort and a Japanese validation cohort with clinical data matched to measures of blood lactate. The primary outcome was survival from onset to death or tracheostomy. In the exploratory cohort, survival was analyzed using Kaplan-Meier curves stratified by the first quartile (Q1) of lactate and multivariable Cox regression. This cutoff was applied for log-rank analysis in the validation cohort. The secondary outcome was 3-month body mass index (BMI) change (ΔBMI). Associations between baseline lactate and ΔBMI were assessed using multivariable regression in the exploratory cohort, whereas Q1-based stratification was used in the validation cohort. RESULTS: The exploratory cohort included 110 patients with ALS (57 with ΔBMI data) and 86 healthy controls; the validation cohort included 36 patients (17 with ΔBMI data). In the exploratory cohort, lower lactate levels (below Q1; 1.05 mmol/L) were associated with shorter survival (p = 0.031) and remained independently predictive of higher risk for mortality (adjusted hazard ratio [HR] per 1 SD = 0.57, 95% confidence interval [CI] = 0.35-0.91). This association was confirmed in the validation cohort (p = 0.003). Lactate was independently associated with ΔBMI (β = 0.53, p = 0.032), and patients with lower lactate had a greater BMI decline (p = 0.010). INTERPRETATION: Lower blood lactate is associated with increased risk for earlier death and greater weight loss in ALS, suggesting that lactate is a prognostic biomarker of nutritional status. ANN NEUROL 2026;99:1526-1535.
引用
- Nakamura R, Steyn FJ, Kobashi S, et al. Blood Lactate as a Prognostic Biomarker for Survival and Weight Loss in Amyotrophic Lateral Sclerosis: An Exploratory-Validation Study. Ann Neurol. 2026. PMID: 41744269. doi:10.1002/ana.78184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。